Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study.
Eric LawitzFred PoordadJulio A GutierrezMaria BeumontGreet BeetsAnn VandevoordePieter Van RemoortereDonghan LuoLeen VijgenVeerle Van EygenMohamed GamilPublished in: Health science reports (2020)
In the IMPACT study, virologic response to simeprevir, sofosbuvir, and daclatasvir was durable over 3 years (http://ClinicalTrials.gov number: NCT02262728).